Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. The table below offers a ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Regeneron (REGN) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

Clearly, options traders are pricing in a big move for Regeneron Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Regeneron Pharmaceuticals is a Zacks Rank ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron (REGN) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $11.69 a share five days away from its upcoming earnings release on February 4, 2025. Regeneron's ...